Our observation that 53% of the NSCLC tumor samples highly expressed PKR and that 61% of them highly expressed p-PKR [data not shown] These results led us to speculate that PKR expression (i.e., PKR) and PKR activation (i.e., p-PKR) are affected by differing expression of the PKR activator or PKR inhibitor. Here, EIF2AK2 is linked to non-small cell lung carcinoma.